Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Atossa Genetics (NASDAQ:ATOS) posted its quarterly earnings results on Friday. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.09, FiscalAI reports.

Atossa Genetics Price Performance

Shares of ATOS stock traded down $0.06 during trading hours on Friday, hitting $2.36. The company had a trading volume of 77,520 shares, compared to its average volume of 66,253. The stock has a market capitalization of $20.32 million, a PE ratio of -0.74 and a beta of 1.29. The company’s fifty day moving average is $2.62 and its 200 day moving average is $4.51. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Atossa Genetics by 51.3% in the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after buying an additional 37,809 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares during the period. Jane Street Group LLC purchased a new position in Atossa Genetics during the 2nd quarter valued at about $381,000. Ameriprise Financial Inc. acquired a new position in Atossa Genetics in the 2nd quarter valued at about $2,468,000. Finally, Hudson Bay Capital Management LP acquired a new position in Atossa Genetics in the 2nd quarter valued at about $26,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ATOS. Rodman & Renshaw initiated coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price objective for the company. Ascendiant Capital Markets cut their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a report on Friday, April 10th. Finally, Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.